Eric Archambeau
Angel Investor @ Wellington Partners
London, United Kingdom
Eric Archambeau is a Series A investor at Wellington Partners in London focused on Software and E-Commerce. Eric Archambeau is based out of Switzerland and is the Founder and Senior Managing Partner of Astanor Ventures and also the Board Observer of Omeza. Eric previously worked at Quadia as a Chairman. Eric Archambeau attended Stanford University.
- Total investments:
- 30
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Eric Archambeau invests in
Stages Eric Archambeau invests in
Countries Eric Archambeau invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $550k–$18M
- Series A
- $4.6M–$20M
- Series B
- $6M–$29M
Investment Focus
Industry
- Software 6 (20%)
- E-Commerce 5 (17%)
- Apps 4 (13%)
- Music 4 (13%)
- Mobile 4 (13%)
Stage
- Series A 11 (37%)
- Series B 8 (27%)
- Seed 3 (10%)
- Venture - Series Unknown 3 (10%)
- Funding Round 2 (7%)
Country
- United States 7 (23%)
- United Kingdom 5 (17%)
- France 3 (10%)
- Sweden 3 (10%)
- Finland 2 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RFI Ingredients is a formulation-driven company, that engages in providing exceptional products, solutions, and services for the dietary supplement, beverage, and food industries. | Venture - Series Unknown / Jul 28, 2026 | ||
| Omeza is a hospital and healthcare company that provides wound care, venous leg ulcers, omega 3, and innovation. The company is driven by its mission is to improve healthcare efficiency one market at a time, beginning with wound care. The company was founded in 2014 and headquartered in Florida, United States. | $8.5M / Series A / Apr 21, 2026 | ||
| Standing Ovation develops food technology solutions using precision fermentation to produce animal-free dairy proteins for food manufacturing. The company creates casein proteins through engineered microorganisms, enabling the production of cheese and other dairy products without relying on traditional animal farming.Its core product, AdvancedCasein, is designed to replicate the functional, nutritional, and taste properties of conventional milk proteins while reducing dependence on livestock-based supply chains. The production process involves cultivating microorganisms, feeding them plant-based inputs, and extracting proteins that can be incorporated into standard dairy processing methods. Standing Ovation applies these proteins in the development of cheese alternatives that follow traditional cheesemaking techniques, allowing compatibility with existing manufacturing systems. The resulting products are lactose-free and aim to maintain similar texture and performance characteristics as conventional dairy ingredients in food applications. | $28.6M / Series B / Mar 31, 2026 | ||
| Laced is a marketplace for the buying and selling of authentic sneakers, connecting thousands of buyers and sellers worldwide. | $12M / Series A / May 24, 2023 | ||
| Standing Ovation develops food technology solutions using precision fermentation to produce animal-free dairy proteins for food manufacturing. The company creates casein proteins through engineered microorganisms, enabling the production of cheese and other dairy products without relying on traditional animal farming.Its core product, AdvancedCasein, is designed to replicate the functional, nutritional, and taste properties of conventional milk proteins while reducing dependence on livestock-based supply chains. The production process involves cultivating microorganisms, feeding them plant-based inputs, and extracting proteins that can be incorporated into standard dairy processing methods. Standing Ovation applies these proteins in the development of cheese alternatives that follow traditional cheesemaking techniques, allowing compatibility with existing manufacturing systems. The resulting products are lactose-free and aim to maintain similar texture and performance characteristics as conventional dairy ingredients in food applications. | $12M / Series A / Sep 14, 2022 | ||
| Kuleana creates plant-based alternatives for people's seafood favorites, using plants and biotechnology without the environmental and ethical consequences. | $18M / Seed / Jun 23, 2022 | ||
| SignalRank owns a growing asset portfolio of top performing venture backed companies. It enters at Series B by helping early stage investors maintain their ownership in their best assets. The resulting portfolio is a top decile venture performer since inception in May 2023. SignalRank finances early stage investors’ pro-rata in qualifying Series B rounds through an automated process designed for speed, high-conviction selection, and partner-aligned economics. it can decide inside 24 hours and fund in less than a week. As a result SignalRank has 300+ seed partners who invite it to partner for pro-rata financing in their fastest growing companies. It sees a high percentage of all Series B term sheets prior to close. Capital is supplied from SignalRank’s balance sheet, with no capital calls or partner IC process delays. Check size correlates with capital available. SignalRank handles SPV setup and ongoing administration, with a target of moving from partner allocation request to funding in 5 business days. 20% of the profit on each investment goes directly to partners. SignalRank creates deal-by-deal SPVs; SignalRank does not charge management fees for this partner product. The portfolio can be seen at - https://signalrank.com/signalrank-index.html | $5.1M / Seed / Nov 14, 2021 | ||
| We set off with a first vision: to create a cheese that is superior in taste and nutrition, constantly striving to use our planet’s resources wisely, accessible to all yet one of the top preferred cheeses by chefs and restaurants. Simply put, the world’s most ambitious cheese. | $19.6M / Series A / Sep 02, 2021 | ||
| Modern Meadow is developing fundamentally new approaches to growing animal products. This includes cultured leather and meat products that require no animal slaughter and much lower inputs of land, water, energy, and chemicals. | $130M / Series C / Apr 29, 2021 | ||
| Import.io is the number one Web Data Integration provider. Import.io deliver the world’s data directly to enterprises, fueling business insight and competitive advantage. The Import.io Web Data Integration solution extracts, prepares and integrates high-quality comprehensive web data into customers’ analytics platforms and business applications.The company delivers data to more than 850 customers from millions of web sources. | $15.5M / Series B / Dec 18, 2018 | ||
| See all 30 investments → | |||
Co-Investors
About Wellington Partners
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically lead financing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million. Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Wellington Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Erich Schlick
General Partner
|
|||
Rolf Christof Dienst
General Partner and Founder Emeritus
|
|||
Anja Weibel
Finance Manager
|
|||
Frank Boehnke
General Partner
|
|||
Harald Keller
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eric Archambeau invest in?
Eric Archambeau invests primarily in Software, E-Commerce and Apps startups, most often at Series A and Series B stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Eric Archambeau invest in?
Eric Archambeau typically joins rounds of $550k–$18M at Seed, $4.6M–$20M at Series A and $6M–$29M at Series B. These are whole funding-round sizes, not Eric Archambeau's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Eric Archambeau took part in.
How do I contact Eric Archambeau?
Public channels for Eric Archambeau include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eric Archambeau last invest?
The most recent investment recorded for Eric Archambeau closed in Jul 2026. Shizune tracks 30 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
